StockIQ.techWest Pharmaceutical Services Inc. (WST) Stock Analysis
Free AI-powered analysis and research for West Pharmaceutical Services Inc. stock
Sector: Healthcare
WST snapshot
Data as of 4 Nov 2026 close. Updated daily.
West Pharmaceutical Services Inc. scores 97/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 86% of its 52-week range, up 42.0% over the past year. Latest reported figures show a profit margin of 17.0%, return on equity of 19.1% and revenue growth of +13.8%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- High P/E (51.7): -10
- Good Profit Margin (17.0%): +5
- Low Debt (0.11 D/E): +8
- Strong Liquidity (2.82 Current Ratio): +8
- Strong ROE (19.1%): +5
- High P/B (9.50): -5
- Strong Long-term Uptrend: +8
- Strong Momentum (+42.0% over 1 year): +8
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full WST report
West Pharmaceutical Services Inc. (WST) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze WST Now →📰 Latest Update
What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call
Sat, October 31, 2026 at 6:14 AM UTC 4 min read
During its Q3 earnings call, West Pharmaceutical Services (WST) reported strong revenue growth driven by increased demand for its pharmaceutical packaging and delivery solutions. The company highlighted ongoing investments in capacity expansion to meet future needs, which is crucial for maintaining its competitive edge. For investors, this positive outlook suggests continued momentum in the biopharmaceutical sector, potentially leading to sustained financial performance and shareholder value.